Newsroom
Latest News
News
SERA PROGNOSTICS REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS
SALT LAKE CITY, Nov. 9, 2022 /PRNewswire/ — Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today…
News
Sera Prognostics Announces Conference Call and Webcast of Third Quarter Fiscal Year 2022 Financial Results on November 9
Sera Prognostics announced that it will report third quarter fiscal year 2022 financial results on Wednesday, November 9, 2022, after the close of the market.
News
SONRAVA HEALTH TO INCLUDE THE PreTRM® TEST IN ITS EMPLOYEE MATERNITY BENEFITS PACKAGE IN COLLABORATION WITH CEREBRAE AND SERA PROGNOSTICS
Sera Prognostics Inc., focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, Sonrava Health, a national family of health and wellness companies, and Cerebrae, an innovator in pricing and measuring the financial value of care, are collaborating to provide Sera’s PreTRM® Test to members of Sonrava Health’s employer-sponsored health insurance program.
News
BANNER HEALTH, SERA PROGNOSTICS TEAM UP TO PROVIDE PreTRM® TEST TO COVERED PREGNANT MEMBERS
Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), and Banner Health today announced that Sera’s PreTRM® Test will be available to Banner – University Family Care/ AHCCCS Complete Care (B – UFC/ACC) members.
News
SERA PROGNOSTICS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS
Salt Lake City – August 10, 2022 – Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the second quarter ended June 30, 2022.
News
Sera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2022 Financial Results on August 10
Salt Lake City, July 28, 2022 —Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and…
News
SERA PROGNOSTICS TO PRESENT AT 42nd ANNUAL WILLIAM BLAIR GROWTH STOCK CONFERENCE
Salt Lake City – June 6, 2022 – Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to…
News
SERA PROGNOSTICS ANNOUNCES PUBLICATION OF DATA DEMONSTRATING IMPROVED PERFORMANCE OF ITS PRETRM® TEST WITH MORE PRECISE GESTATIONAL AGE
Results show that the validated proteomics predictor has even greater predictive performance to determine risk of spontaneous preterm birth Salt Lake City – May 19, 2022 –Sera Prognostics Inc., The…
News
SERA PROGNOSTICS PRESENTS DATA DEMONSTRATING THE HEALTH AND ECONOMIC BENEFIT OF PRETRM® TESTING AT ISPOR ANNUAL MEETING
SALT LAKE CITY, May 18, 2022 /PRNewswire/ — Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and…
News
SERA PROGNOSTICS AND NEWBORN FOUNDATION PARTNER TO REDUCE RISKS ASSOCIATED WITH PRETERM BIRTH AND IMPROVE HEALTH EQUITY THROUGH THE “EVERY MOTHER, EVERY BABY” PROJECT
Project focused on reducing maternal and neonatal mortality and morbidity by mitigating risks associated with unanticipated preterm birth SALT LAKE CITY, May 5, 2022 Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused…